An open-label, dose-escalating phase I study of elsamitrucin (SPI 28090) in treatment of malignant solid tumors in dogs

Journal of Veterinary Internal Medicine

Volumn 25, Issue 4, 2011, Pages 897-902

  Fiocchi, S C ^a   Selting, K A ^b   Rosenberg, M P ^a   Kolli, P ^c   Lenaz, G ^c   Henry, C ^b  

^a Veterinary Cancer Group   (United States)

^b UNIVERSITY OF MISSOURI   (United States)

^c Spectrum Pharmaceuticals   (United States)

Author keywords

Antitumor antibiotic; Chemotherapy; Topoisomerase II inhibitor; Toxicity

Indexed keywords

AMINOGLYCOSIDE; ANTINEOPLASTIC ANTIBIOTIC; ELSAMICIN A;

ANIMAL; ANIMAL DISEASE; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; DOG; DOG DISEASE; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; MALE; MAXIMUM TOLERATED DOSE; MULTICENTER STUDY; NEOPLASM; PATHOLOGY; PHASE 1 CLINICAL TRIAL; PROSPECTIVE STUDY;

AMINOGLYCOSIDES; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; COHORT STUDIES; DOG DISEASES; DOGS; FEMALE; INFUSIONS, INTRAVENOUS; MALE; MAXIMUM TOLERATED DOSE; NEOPLASMS; PROSPECTIVE STUDIES;

ANIMALIA; CANIS FAMILIARIS;

EID: 79960554728     PISSN: 08916640     EISSN: 19391676     Source Type: Journal    
DOI: 10.1111/j.1939-1676.2011.0752.x     Document Type: Article

References (11)

1. Konishi M, Sugawara K, Kofu F, et al. Elsamicins, new antitumor antibiotics related to chartreusin. I. Production, isolation, characterization and antitumor activity. J Antibiot (Tokyo) 1986;39:784-791.
2. Lorico A, Long BH. Biochemical characterisation of elsamicin and other coumarin-related antitumour agents as potent inhibitors of human topoisomerase II. Eur J Cancer 1993;29A:1985-1991.
3. Schurig JE, Bradner WT, Basler GA, et al. Experimental antitumor activity of BMY-28090, a new antitumor antibiotic. Invest New Drugs 1989;7:173-178.
4. Raber MN, Newman RA, Newman BM, et al. Phase I trial and clinical pharmacology of elsamitrucin. Cancer Res 1992;52:1406-1410.
5. Allen SL, Schacter LP, Lichtman SM, et al. Phase II study of elsamitrucin (BMY-28090) for the treatment of patients with refractory/relapsed non-Hodgkin's lymphoma. Invest New Drugs 1996;14:213-217.
6. Verweij J, Wanders J, Nielsen AL, et al. Phase II studies of elsamitrucin in breast cancer, colorectal cancer, non-small cell lung cancer and ovarian cancer. EORTC Early Clinical Trials Group. Ann Oncol 1994;5:375-376.
7. Goss G, Letendre F, Stewart D, et al. Phase II study of elsamitrucin in non-small cell lung cancer. Invest New Drugs 1994;12:315-317.
8. Veterinary Co-operative Oncology Group. Common Terminology Criteria for Adverse Events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1. Vet Comp Oncol 2004;2:195-213.
9. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216.
10. Hillman SL, Mandrekar SJ, Bot B, et al. Evaluation of the value of attribution in the interpretation of adverse event data: A north central cancer treatment group and American college of surgeons oncology group investigation. J Clin Oncol 28:3002-3007.
11. Mukherjee SD, Coombes ME, Levine M, et al. A qualitative study evaluating causality attribution for serious adverse events during early phase oncology clinical trials. Invest New Drugs; DOI DOI: 10.1007/s10637-010-9456-9.